BioMarin Pharmaceutical Inc. (BMRN) can make a big difference with a little luck

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock fell -4.30% on Thursday to $87.68 against a previous-day closing price of $91.62. With 1.41 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.27 million shares. The 52-week range on BMRN shows that it touched its highest point at $117.77 and its lowest point at $80.53 during that stretch. It currently has a 1-year price target of $116.56. Beta for the stock currently stands at 0.36.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BMRN was down-trending over the past week, with a drop of -3.03%, but this was down by -3.30% over a month. Three-month performance dropped to -7.13% while six-month performance fell -0.07%. The stock gained 1.32% in the past year, while it has lost -15.28% so far this year. A look at the trailing 12-month EPS for BMRN yields 0.51 with Next year EPS estimates of 2.51. For the next quarter, that number is 0.23. This implies an EPS growth rate of 301.40% for this year and 144.92% for next year.

Float and Shares Shorts:

At present, 187.95 million BMRN shares are outstanding with a float of 187.02 million shares on hand for trading. On Aug 30, 2023, short shares totaled 6.25 million, which was 3.32% higher than short shares on Jul 30, 2023. In addition to Mr. Jean-Jacques Bienaime M.B.A., MBA as the firm’s Chairman & CEO, Mr. Brian R. Mueller serves as its CFO & Exec. VP.

Institutional Ownership:

Through their ownership of 97.77% of BMRN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 57.34% of BMRN, in contrast to 38.82% held by mutual funds. Shares owned by individuals account for 1.99%. As the largest shareholder in BMRN with 9.79% of the stake, PRIMECAP Management Co. holds 18,383,619 shares worth 18,383,619. A second-largest stockholder of BMRN, The Vanguard Group, Inc., holds 17,339,258 shares, controlling over 9.24% of the firm’s shares. Dodge & Cox is the third largest shareholder in BMRN, holding 14,290,303 shares or 7.61% stake. With a 4.72% stake in BMRN, the Dodge & Cox Stock Fund is the largest stakeholder. A total of 8,867,025 shares are owned by the mutual fund manager. The Vanguard PRIMECAP Fund, which owns about 3.56% of BMRN stock, is the second-largest Mutual Fund holder. It holds 6,676,138 shares valued at 587.03 million. Vanguard Total Stock Market ETF holds 3.13% of the stake in BMRN, owning 5,878,821 shares worth 516.92 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, BMRN reported revenue of $533.80M and operating income of $39.15M. The EBITDA in the recently reported quarter was $63.98M and diluted EPS was $0.15.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BMRN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BMRN analysts setting a high price target of $185.00 and a low target of $78.00, the average target price over the next 12 months is $116.87. Based on these targets, BMRN could surge 110.99% to reach the target high and fall by -11.04% to reach the target low. Reaching the average price target will result in a growth of 33.29% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded BMRN stock several times over the past three months with 0 Buys and 9 Sells. In these transactions, 0 shares were bought while 53,140 shares were sold. The number of buy transactions has increased to 64 while that of sell transactions has risen to 59 over the past year. The total number of shares bought during that period was 789,349 while 396,679 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *